The slower rollout of Wegovy in new markets may cause a temporary slowdown in revenue growth for Novo Nordisk. However, the higher than expected demand for the drug indicates a strong market potential, which could lead to increased revenue in the long term. This mixed impact on the stock price makes it difficult to predict a clear short-term direction.